文献速递淋巴瘤白血病

靶向CD38可杀伤Breg样慢性淋巴细胞白血病细胞与Treg并恢复CD8+ T细胞应答

Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses.
PubMed 文献 · Blood Adv · 2020-01-01

研究探讨慢性淋巴细胞白血病(CLL)中CD19+CD24+CD38hi的Breg样CLL细胞与Treg的免疫抑制功能,发现抗CD38靶向药物可经凋亡杀伤Breg样CLL细胞与Treg,在体外和CLL患者来源异种移植模型中降低IL-10与Treg、增加干扰素-γ与CD8+ T细胞增殖及杀伤自体CLL细胞的能力,从而将免疫抑制微环境扭转为免疫反应性环境。

要点

  • Breg样CLL细胞(CD19+CD24+CD38hi)高分泌IL-10与TGF-β,可诱导naive Th细胞转化为Treg。
  • CD38+ CLL细胞比例与Treg比例呈强相关;CD38hi Treg占CLL患者PBMC中Treg的50%以上。
  • 抗CD38单抗在体外降低IL-10与Treg、增加干扰素-γ与CD8+ T细胞增殖,在CLL患者来源异种移植模型中降低Bregs、Tregs与PD1+CD38hiCD8+ T细胞、增加Th17与CD8+ T细胞(vs 对照)。

核心结论

  • 在CLL中靶向CD38可调节肿瘤微环境,使T细胞群体从免疫抑制转向免疫反应状态,从而促进免疫重建以增强抗CLL应答。

研究设计与样本

  • 研究为CLL细胞免疫功能与抗CD38靶向治疗的实验研究,包括体外实验与CLL患者来源异种移植模型体内验证。

主要发现

  • CD19+CD24+CD38hi免疫表型的Breg样CLL细胞产生大量IL-10与TGF-β,并以IL-10/TGF-β依赖方式将naive Th细胞转化为CD4+CD25+FoxP3+ Treg。
  • 观察到CD38+ CLL细胞百分比与Treg之间存在强相关,CD38hi Treg占CLL患者PBMC中Treg的50%以上。
  • 抗CD38靶向药物经凋亡导致Breg样CLL细胞与Treg细胞死亡。
  • 体外抗CD38单抗治疗与IL-10及CLL患者来源Treg减少相关,同时干扰素-γ与具有活化表型的细胞毒性CD8+ T细胞增殖增加,后者裂解患者自体CLL细胞的能力改善。
  • CLL患者来源异种移植模型体内显示,抗CD38单抗治疗较对照降低Bregs、Tregs与PD1+CD38hiCD8+ T细胞百分比,增加Th17与CD8+ T细胞。

关键数值与推荐

  • Breg样CLL细胞定义为CD19+CD24+CD38hi免疫表型,高分泌IL-10与TGF-β。
  • CD38hi Treg占CLL患者PBMC中Treg的50%以上。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with chronic lymphocytic leukemia (CLL) are characterized by monoclonal expansion of CD5+CD23+CD27+CD19+κ/λ+ B lymphocytes and are clinically noted to have profound immune suppression. In these patients, it has been recently shown that a subset of B cells possesses regulatory functions and secretes high levels of interleukin 10 (IL-10). Our investigation identified that CLL cells with a CD19+CD24+CD38hi immunophenotype (B regulatory cell [Breg]-like CLL cells) produce high amounts of IL-10 and transforming growth factor β (TGF-β) and are capable of transforming naive T helper cells into CD4+CD25+FoxP3+ T regulatory cells (Tregs) in an IL-10/TGF-β-dependent manner. A strong correlation between the percentage of CD38+ CLL cells and Tregs was observed. CD38hi Tregs comprised more than 50% of Tregs in peripheral blood mononuclear cells (PBMCs) in patients with CLL. Anti-CD38 targeting agents resulted in lethality of both Breg-like CLL and Treg cells via apoptosis. Ex vivo, use of anti-CD38 monoclonal antibody (mAb) therapy was associated with a reduction in IL-10 and CLL patient-derived Tregs, but an increase in interferon-γ and proliferation of cytotoxic CD8+ T cells with an activated phenotype, which showed an improved ability to lyse patient-autologous CLL cells. Finally, effects of anti-CD38 mAb therapy were validated in a CLL-patient-derived xenograft model in vivo, which showed decreased percentage of Bregs, Tregs, and PD1+CD38hiCD8+ T cells, but increased Th17 and CD8+ T cells (vs vehicle). Altogether, our results demonstrate that targeting CD38 in CLL can modulate the tumor microenvironment; skewing T-cell populations from an immunosuppressive to immune-reactive milieu, thus promoting immune reconstitution for enhanced anti-CLL response.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Manna A, Kellett T, Aulakh S, et al. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. Blood Adv. 2020. PMID: 32421811. doi:10.1182/bloodadvances.2019001091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。